Rep. Robert Bresnahan, Jr. Sells Off Shares of IQVIA Holdings Inc. (NYSE:IQV)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of IQVIA Holdings Inc. (NYSE:IQV). In a filing disclosed on May 31st, the Representative disclosed that they had sold between $1,001 and $15,000 in IQVIA stock on May 15th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Zimmer Biomet (NYSE:ZBH) on 5/15/2025.
• Sold $15,001 – $50,000 in shares of Elevance Health (NYSE:ELV) on 5/15/2025.
• Sold $15,001 – $50,000 in shares of PepsiCo (NASDAQ:PEP) on 5/15/2025.
• Sold $1,001 – $15,000 in shares of WEC Energy Group (NYSE:WEC) on 5/15/2025.
• Purchased $15,001 – $50,000 in shares of Advanced Micro Devices (NASDAQ:AMD) on 5/15/2025.
• Purchased $1,001 – $15,000 in shares of Hershey (NYSE:HSY) on 5/15/2025.
• Purchased $1,001 – $15,000 in shares of Kraft Heinz (NASDAQ:KHC) on 5/15/2025.
• Sold $1,001 – $15,000 in shares of Exxon Mobil (NYSE:XOM) on 5/15/2025.
• Sold $1,001 – $15,000 in shares of Danaher (NYSE:DHR) on 5/15/2025.
• Sold $1,001 – $15,000 in shares of International Flavors & Fragrances (NYSE:IFF) on 5/15/2025.

IQVIA Stock Down 0.9%

IQV stock opened at $139.06 on Tuesday. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The company has a market capitalization of $24.06 billion, a price-to-earnings ratio of 18.54, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. The business’s 50 day moving average price is $149.98 and its two-hundred day moving average price is $180.19. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The business had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. During the same quarter in the previous year, the firm posted $2.54 earnings per share. IQVIA’s quarterly revenue was up 2.5% on a year-over-year basis. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On IQVIA

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. American National Bank & Trust acquired a new position in shares of IQVIA in the 1st quarter worth approximately $26,000. Clal Insurance Enterprises Holdings Ltd raised its position in IQVIA by 436.7% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 131 shares during the period. Golden State Wealth Management LLC lifted its stake in IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock worth $31,000 after purchasing an additional 130 shares in the last quarter. Synergy Asset Management LLC purchased a new position in shares of IQVIA during the fourth quarter worth $33,000. Finally, AllSquare Wealth Management LLC acquired a new stake in shares of IQVIA in the first quarter valued at $33,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on IQV. UBS Group decreased their target price on shares of IQVIA from $255.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. HSBC downgraded shares of IQVIA from a “buy” rating to a “hold” rating and decreased their price target for the stock from $260.00 to $160.00 in a research report on Friday, April 25th. BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Morgan Stanley upped their price objective on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Finally, Citigroup reiterated a “neutral” rating on shares of IQVIA in a research report on Thursday, May 22nd. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $226.32.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.